AstraZeneca Sells Gastro Treatment to Swiss Group Tillotts

In another move to sharpen its focus on oncology, diabetes and respiratory disorders, AstraZeneca has announced it is selling all non-US rights for Entocort, a treatment for Crohn’s disease and ulcerative colitis, for $215 million to Tillotts Pharma of Switzerland.

Tillotts is part of the Japanese Zeria Group.

In 2014, Entocort had sales of $53 million in 40 countries. Outside the US, the drug is sold through Par Pharmaceutical, a partnership which will be continued under the new owner.

The Swedish-British drugmaker has already shed its antibiotics portfolio and brought its experimental dementia drug into a partnership with Eli Lilly. Most recently, it sold co-marketing rights for a new constipation treatment for $200 million to Daiichi Sankyo of Japan.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.